Fig. 2: Sensitivity of the SARS-CoV-2 variants D614G, Delta and Omicron to sera from vaccinated, convalescent or infected-then-vaccinated individuals.
From: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Neutralization titres of the sera against the three indicated viral variants are expressed as ED50. a, Neutralizing activity of sera from individuals who were vaccinated with the AstraZeneca (n = 18; left) and Pfizer (n = 16; right) vaccines, sampled at 5 months after the second dose. b, Neutralizing activity of sera from Pfizer-vaccinated recipients sampled one month (M1) after the third injection. n = 20. The dotted line indicates the limit of detection (ED50 = 30). c, The neutralizing activity of sera from convalescent individuals (n = 16), sampled at 6 months after the onset of symptoms (left). Middle, the neutralizing activity of sera from convalescent individuals (n = 23), sampled at 12 months after the onset of symptoms. Right, the neutralizing activity of sera from individuals who were infected then vaccinated (n = 22), sampled one month after the first injection (right). In each panel, data are the mean values from two to three independent experiments. Two-sided Friedman tests with Dunn’s multiple-comparison correction was performed to compare D614G and Omicron with the Delta variant; *P < 0.05, **P < 0.01, ***P < 0.001.
